Pacific Edge Limited (PEB.NZ)

0.1080 +0.0050 (+4.85%) 市場開市。 截至 11:22AM NZST。

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 114

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Peter Meintjes	Chief Executive Officer	無	無	無
Mr. Grant Gibson	Chief Financial Officer	無	無	無
Mr. Darrell Morgan	Chief Operating Officer	無	無	無
Dr. Justin Harvey	Chief Technology Officer	無	無	無
Prof. Parry Guilford Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	134k	無	無
Mr. Jack Atchason	Senior Vice President of Sales - Pacific Edge Diagnostics USA Limited	無	無	無
Mr. Andrew McIntosh	Chief Digital Officer	無	無	無
Glen Costin	President of Asia Pacific	無	無	無
Dr. Tamer Aboushwareb	Chief Medical Officer	無	無	無
Mr. David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	53k	無	1960

截止 2009年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 NZD。

描述

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

公司管治

截至 2024年5月1日 止，Pacific Edge Limited 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：6；董事會：2；股東權利：7；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。